Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (Fluzone high-dose) and guidance for use-United States, 2010

Morbidity and Mortality Weekly Report

Volumn 59, Issue 16, 2010, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951901965     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40.
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
3. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-69.
4. CDC. ACIP provisional recommendations for the use of influenza vaccines. Atlanta, GA, US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/vaccines/recs/provisional/downloads/flu-vac-mar-2010-508.pdf. Accessed April 23, 2010.
5. CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009;58(No. RR-8).
6. Sanofi Pasteur, Inc. Fluzone and Fluzone High-Dose [prescribing information]. Swiftwater, PA: Sanofi Pasteur, Inc.; 2009. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/ucm195479.pdf. Accessed April 23, 2010.
7. Food and Drug Administration. Influenza virus vaccine for the 2010-2011 season. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2010. Available at http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/post-marketactivities/lotreleases/ucm202750.htm. Accessed April 23, 2010.
8. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007;25:7656-63.
9. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172-80.
10. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006;166:1121-7.